



ASX Announcement | 4 October 2019
Althea Group Holdings (ASX:AGH)

Althea reaches 2,329 patients in September & NSW simplifies patient access

INVESTMENT HIGHLIGHTS:

- 2,329 patients have now been prescribed Althea medicinal cannabis products in Australia
- 462 patients were added in September, representing the largest number of patients prescribed Althea products in a single month to date
- NSW Health has simplified the requirements for prescribers of medicinal cannabis in NSW, Australia's most populous state, with patient uptake expected to accelerate


4 October 2019: Australian medicinal cannabis company Althea Group Holdings Limited (ASX:AGH) ('Althea' or 'the Company') is pleased to provide the following update regarding the uptake of its medicinal cannabis products in Australia.

September another record-breaking month for patient uptake

Althea welcomed 462 new patients in September at a rate of 22 patients per business day, representing the largest number of new patients prescribed Althea medicinal cannabis products in a single month. The month on month growth rate in new patients per business day was approximately 22.2%.

In addition, there are now 319 Australian Healthcare Professionals ('HCPs') who have prescribed Althea's products.

Chart 1: Patient Growth





NSW Health simplifies requirements for prescribers of medicinal cannabis

NSW Health has simplified the requirements for prescribers of medicinal cannabis in NSW, Australia's most populous state. From 30 September 2019, in most cases only a Therapeutic Goods Administration issued approval will be required.

The Company expects patient uptake of Althea medicinal cannabis products within NSW to accelerate due to the softening of the regulations. The Company views the changes as signifying the growing acceptance of medicinal cannabis by government, reflecting that of the medical community.

Patient increase driven by Althea's strategy and favourable regulatory backdrop

The rapid uptake of Althea's medicinal cannabis products is being driven by the Company's two-pronged strategy comprised of an on-the-ground Medical Science Liaison team and *Althea Concierge*, a proprietary platform that greatly reduces application times for HCP's prescribing Althea medicinal cannabis products.

Althea CEO Josh Fegan said: "We are very pleased to have exceeded our estimates with regard to patient uptake in Australia. In June, we achieved our 1,000 patient milestone almost six months ahead of schedule and less than three months later we have reached 2,329 patients. The recent developments in NSW are further signs of the normalisation of cannabis-based medicines and a great win for patient access, in which Althea is clearly leading the way. Our education-focussed approach has been a huge success in Australia and we are replicating it in the UK and other markets."

-ENDS-

For further information, please contact:

Althea

Josh Fegan

CEO & Managing Director

M: 1300 70 20 20

E: contact@althea.life

Media Enquiries

Julia Maguire

The Capital Network

M: +61 419 815 386

E: julia@thecapitalnetwork.com.au

Australian Investors

PAC Partners Securities

M: 03 9114 7401

E: enquiries@pacpartners.com.au

Althea Group Holdings Limited (ASX:AGH)

Althea is an Australian licensed producer, supplier and exporter of pharmaceutical grade medicinal cannabis and is listed publicly on the Australian Securities Exchange (ASX:AGH). Althea also offers a range of education, access and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways.

Althea currently operates within highly regulated medicinal cannabis markets including Australia and the United Kingdom, with plans to expand into emerging markets throughout Asia and Europe.

To learn more, please visit: www.althea.life